Neuropathological spectrum of synucleinopathies

Movement Disorders

Volumn 18, Issue SUPPL. 6, 2003, Pages

  Jellinger, Kurt A ^a  

^a INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

Inclusion bodies; Lewy body diseases; Multiple system atrophy; Neuropathology; Synucleinopathies

Indexed keywords

ALPHA SYNUCLEIN; IRON;

AMYLOIDOSIS; AUTONOMIC DYSFUNCTION; BRAIN DEGENERATION; CELL INCLUSION; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; GLIA; GLIOSIS; HALLERVORDEN SPATZ DISEASE; HISTOPATHOLOGY; HUMAN; LEWY BODY; NERVE CELL; NEURITE; NEUROAXONAL DYSTROPHY; NEUROPATHOLOGY; NONHUMAN; OLIGODENDROGLIA; OLIVOPONTOCEREBELLAR ATROPHY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN PROCESSING; QUANTITATIVE DIAGNOSIS; REVIEW; SHY DRAGER SYNDROME; STRIATONIGRAL DEGENERATION; SYNUCLEINOPATHY; TAUOPATHY;

EID: 0141725659     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10557     Document Type: Review

References (77)

1. Goedert M, Jakes R, Crowther RA, Spillantini MG. Parkinson' disease, dementia with Lewy bodies, and multiple system atrophy as α-synucleinopathies. In: Mouradian MM, editor. Parkinson's disease: methods and Protocols. Totowa, NJ: Humana Press; 2001. p 33-59.
2. Galvin JE, Giasson B, Hurtig HI, Lee VM, Trojanowski JQ. Neurodegeneration with brain iron accumulation, type 1 is characterized by α-, β-, and γ-synuclein neuropathology. Am J Pathol 2000;157:361-368.
3. Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y. α-Synuclein-positive structures in cases with sporadic Alzheimer's disease: morphology and its relationship to tau aggregation. Brain Res 2001;888:287-296.
4. Dickson DW. α-Synuclein and the Lewy body disorders. Curr Opin Neurol 2001;14:423-432.
5. Yamazaki M, Arai Y, Baba M, et al. α-Synuclein inclusions in amygdala in the brains of patients with the parkinsonism-dementia complex of Guam. J Neuropathol Exp Neurol 2000;59:585-591.
6. Galvin JE, Lee VM, Trojanowski JQ. Synucleinopathies: clinical and pathological implications. Arch Neurol 2001;58:186-190.
7. Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA. Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A 2000;97:4897-4902.
8. Schneider JA, Bienias JL, Gilley DW, Kvarnberg DE, Mufson EJ, Bennett DA. Improved detection of substantia nigra pathology in Alzheimer's disease. J Histochem Cytochem 2002;50:99-106.
9. Goedert M. α-Synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001;2:492-501.
10. Tofaris GK, Layfield R, Spillantini MG. α-Synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett 2001;509:22-26.
11. Fujiwara H, Hasegawa M, Dohmae N, et al. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002;4:160-164.
12. Duda JE, Giasson BI, Chen Q, et al. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol 2000;157:1439-1445.
13. Masliah E, Rockenstein E, Veinbergs I, et al. beta-amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A 2001;98:12245-12250.
14. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature 2000;404:394-398.
15. Lucking CB, Brice A. α-Synuclein and Parkinson's disease. Cell Mol Life Sci 2000;57:1894-1908.
16. Lowe J, Leigh PN. Disorders of movement and system degenerations. In: Graham D, Lantos PL, editors. Greenfield's neuropathology. 7th ed. London: E. Arnold; 2002. p 325-430.
17. Sakamoto M, Uchihara T, Hayashi M, et al. Heterogeneity of nigral and cortical Lewy bodies differentiated by amplified triple-labeling for α-synuclein, ubiquitin, and thiazin red. Exp Neurol 2002;177:88-94.
18. Wakabayashi K, Engelender S, Tanaka Y, et al. Immunocytochemical localization of synphilin-1, an α-synuclein-associated protein, in neurodegenerative disorders. Acta Neuropathol (Berl) 2002;103: 209-214.
19. Jellinger KA, Mizuno Y. Parkinson's disease. In: Dickson DW, et al, editors. Neurodegeneration: The molecular pathology of dementia and movement disorders. Basel: International Society of Neuropathology Press; 2003. p 159-199.
20. Ma SY, Roytta M, Rinne JO, Collan Y, Rinne UK. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts. J Neurol Sci 1997;151:83-87.
21. Rinne JO, Nurmi E, Ruottinen HM, Bergman J, Eskola O, Solin O. [F-18]FDOPA and [F-18]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson disease. Synapse 2001;40:193-200.
22. Jellinger KA. Recent developments in the pathology of Parkinson disease. J Neural Transm 2002(Suppl. 62):347-376.
23. Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 2002;52:205-210.
24. Lozza C, Marie RM, Baron JC. The metabolic substrates of bradykinesia and tremor in uncomplicated Parkinson's disease. Neuroimage 2002;17:688-699.
25. Harding AJ, Stimson E, Henderson JM, Halliday GM. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 2002;125:2431-2445.
26. Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H. Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002;61:413-426.
27. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
28. Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J. Pattern of brain destruction in Parkinson's and Alzheimer's diseases. J Neural Transm 1996;103:455-490.
29. Hurtig HI, Trojanowski JQ, Galvin J, et al. α-Synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000;54:1916-1921.
30. Haroutunian V, Serby M, Purohit DP, et al. Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions. Arch Neurol 2000;57: 1145-1150.
31. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002;59:102-112.
32. Jellinger KA, Seppi K, Wenning GK, Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm 2002;109:329-339.
33. McKeith IG, Ballard CG, Perry RH, Ince PG, O'Brien JT, Neill D, Lowery K, Jaros E, Barber R, Thompson P, Swann A, Fairbairn AF, Perry EK. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000;54: 1050-1058.
34. Ince PG, McKeith IG. Dementia with Lewy bodies. In: Dickson DW, et al, editors. Neurodegeneration: The molecular pathology of dementia and movement disorders. Basel: International Society of Neuropathology Press; 2003. p 188-199.
35. Harding AJ, Halliday GM. Simplified neuropathological diagnosis of dementia with Lewy bodies. Neuropathol Appl Neurobiol 1998; 24:195-201.
36. Higuchi M, Tashiro M, Arai H, et al. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol 2000;162:247-256.
37. Walker Z, Costa DC, Walker RW, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002;73: 134-140.
38. Hansen LA, Samuel W. Criteria for Alzheimer's disease and the nosology of dementia with Lewy bodies. Neurology 1997;48:126-132.
39. Luginger E, Seppi K, Litvan I, et al. Associated Alzheimer pathology modifies the natural history of dementia with Lewy bodies (DB); a clinicopathological study (abstr). Mov Disord 2000; 15(Suppl. 3):226.
40. Hansen LA, Daniel SE, Wilcock GK, Love S. Frontal cortical synaptophysin in Lewy body diseases: relation to Alzheimer's disease and dementia. J Neurol Neurosurg Psychiatry 1998;64: 653-656.
41. Jellinger KA. Prevalence of vascular lesions in dementia with Lewy bodies. A postmortem study. J Neural Transm 2003;110: 771-778.
42. Jellinger KA. Prevalence of cerebrovascular lesions in Parkinson's disease. A postmortem study. Acta Neuropathol (Berl) 2003;105: 415-419.
43. Gomez-Isla T, Growdon WB, McNamara M, et al. Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology 1999;53:2003-2009.
44. Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol (Berl) 2001;102:355-363.
45. Parkkinen L, Soininen H, Alafuzoff I. Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropathol Exp Neurol 2003;62:363-367.
46. Duyckaerts C. Is Parkinson's disease with dementia and dementia with Lewy body the same disease? Answer: no. Mov Disord 2002;17(Suppl. 5):S9.
47. Lees AJ. Parkinson's disease with dementia (PDD) is the same clinicopathological entity as dementia with Lewy bodies (DLB) [abstract]. Mov Disord 2002;17(Suppl. 5):S9.
48. Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y. α-Synuclein-positive structures in cases with sporadic Alzheimer's disease: morphology and its relationship to tau aggregation. Brain Res 2001;888:287-296.
49. DeLucia MW, Cookson N, Dickson DW. Synuclein-immunoreactive Lewy bodies are detected in the amygdala in less than 20% of Alzheimer's disease (AD) cases [abstract]. J Neuropathol Exp Neurol 2002;61:454.
50. Iseki E, Takayama N, Marui W, Ueda K, Kosaka K. Relationship in the formation process between neurofibrillary tangles and Lewy bodies in the hippocampus of dementia with Lewy bodies brains. J Neurol Sci 2002;195:85-91.
51. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 2003;300:636-640.
52. Kaufmann H, Hague K, Perl D. Accumulation of α-synuclein in autonomic nerves in pure autonomic failure. Neurology 2001;56: 980-981.
53. Arnulf I, Bonnet AM, Damier P, et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 2000; 55:281-288.
54. Foltynie T, Sawcer S, Brayne C, Barker RA. The genetic basis of Parkinson's disease. J Neurol Neurosurg Psychiatry 2002;73:363-370.
55. Duda JE, Giasson BI, Mabon ME, et al. Concurrence of α-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol (Berl) 2002;104:7-11.
56. Lantos PL. The definition of multiple system atrophy: a review of recent developments. J Neuropathol Exp Neurol 1998;57:1099-1111.
57. Mochizuki A, Komatsuzaki Y, Shoji S. Association of Lewy bodies and glial cytoplasmic inclusions in the brain of Parkinson's disease. Acta Neuropathol (Berl) 2002;104:534-537.
58. Henderson JM, Gai WP, Hely MA, Reid WG, Walker GL, Halliday GM. Parkinson's disease with late Pick's dementia. Mov Disord 2001;16:311-319.
59. Tsuboi Y, Ahlskog JE, Apaydin H, Parisi JE, Dickson DW. Lewy bodies are not increased in progressive supranuclear palsy compared with normal controls. Neurology 2001;57:1675-1678.
60. Gilman S, Low PA, Quinn N, Albanese A, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163:94-98.
61. Lantos PL, Quinn N. Dementia with Lewy bodies. In: Dickson DW, et al, editors. Neurodegeneration: The molecular pathology of dementia and movement disorders. Basel: International Society of Neuropathology Press; 2003. p 203-219.
62. Gai WP, Pountney DL, Power JH, et al. Alpha-synuclein fibrils constitute the central core of oligodendroglial inclusion filaments in multiple system atrophy. Exp Neurol 2003;181:68-78.
63. Wenning GK, Seppi K, Tison F, Jellinger K. A novel grading scale for striatonigral degeneration (multiple system atrophy). J Neural Transm 2002;109:307-320.
64. Benarroch EE. New findings on the neuropathology of multiple system atrophy. Auton Neurosci 2002;96:59-62.
65. Campbell BC, McLean CA, Culvenor JG, et al. The solubility of α-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J Neurochem 2001; 76:87-96.
66. Taniwaki T, Nakagawa M, Yamada T, et al. Cerebral metabolic changes in early multiple system atrophy: a PET study. J Neurol Sci 2002;200:79-84.
67. Zhou B, Westaway SK, Levinson B. Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001;28:345-349.
68. Curtis AR, Fey C. Morris CM, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001;28:350-354.
69. Castelnau P, Zilbovicius M, Ribeiro MJ, Hertz-Pannier L, Ogier H, Evrard P. Striatal and pontocerebellar hypoperfusion in Hallervorden-Spatz syndrome. Pediatr Neurol 2001;25:170-174.
70. Neumann M, Adler S, Schluter O, Kremmer E, Benecke R, Kretzschmar HA. α-Synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies. Acta Neuropathol (Berl) 2000;100:568-574.
71. LaVaute T, Smith S, Cooperman S, et al. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet 2001;27:209-214.
72. Wakabayashi K, Fukushima T, Koide R, et al. Juvenile-onset generalized neuroaxonal dystrophy (Hallervorden-Spatz disease) with diffuse neurofibrillary and Lewy body pathology. Acta Neuropathol (Berl) 2000;99:331-336.
73. Trojanowski J. Abnormal protein-protein interactions: Underlying mechanisms of diverse neurodegenerative diseases. In: Dickson DW, et al, editors. Neurodegeneration: The molecular pathology of dementia and movement disorders. Basel: International Society of Neuropathology Press; 2003. p. 11-13.
74. Fujiwara H, Hasegawa M, Dohmae N, et al. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002;4:160-164.
75. Chung KK, Dawson VL, Dawson TM. The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci 2001;24(Suppl.):S7-S14.
76. Hasegawa M, Fujiwara H, Nonaka T, et al. Phosphorylated α-synuclein is ubiquitinated in α-synucleinopathy lesions. J Biol Chem 2002 (electronic publication ahead of print: http://www.jbc.org/cgi/reprint/M208046200v1).
77. Betarbet R, Sherer TB, Di Monte DA, Greenamyre JT. Mechanistic approaches to Parkinson's disease pathogenesis. Brain Pathol 2002;12:499-510.